期刊文献+

脂蛋白相关磷脂酶A_2基因沉默对炎症基因表达的影响

Effects of lipoprotein associated phospholipase A_2 gene silencing regulating the expression of inflammatory genes
下载PDF
导出
摘要 目的:观察氧化低密度脂蛋白(oxygenized low density lipoprotein,oxLDL)和脂蛋白相关磷脂酶A2(lip-oprotein associated phospholipase A2,Lp-PLA2)短发夹RNA(shRNA)对小鼠单核巨噬细胞(RAW264.7)Lp-PLA2活性、mRNA表达及炎症基因表达的影响。方法:采用0、20、40、60和80μg/ml oxLDL刺激RAW264.7细胞并用不同剂量Lp-PLA2shRNA转染oxLDL 60μg/ml处理组,应用ELISA、逆转录-聚合酶链反应检测Lp-PLA2、单核细胞趋化蛋白-1(Monocyte Chemoattractant Protein-1,MCP-1)及其mRNA表达的影响。结果:RAW264.7细胞经oxLDL刺激后Lp-PLA2表达明显升高,且呈时间和剂量依赖性。Lp-PLA2shRNA转染小鼠单核巨噬细胞后,炎症基因及mRNA表达明显下降。结论:Lp-PLA2shRNA转染可明显逆转oxLDL刺激引起的RAW264.7细胞炎症基因高表达。 Objective: To identify the effects of lipoprotein associated phospholipase A2(Lp-PLA2) shRNA and oxygenized low density lipoprotein(oxLDL) on the expression of Lp-PLA2 and inflammatory gene expression in mouse monocyte-macrophages. Methods: After 0,20,40,60 and 80μg/ml oxLDL and 60μg/ml oxLDL with different dosage of Lp-PLA2 shRNA treating RAW264.7 cells for 12 hours,Lp-PLA2 and inflammatory gene expression were detected by ELISA kit,and mRNA level of Lp-PLA2 and MCP-1 were detected by RT-PCR. Results: oxLDL increased the activity of Lp-PLA2 and its mRNA expression in a dose and concentration dependent manner,Lp-PLA2 shRNA at varied concentration could inhibit Lp-PLA2 and MCP-1 activity and its mRNA expression induced by oxLDL. Conclusion: Lp-PLA2 shRNA could inhibit Lp-PLA2 and inflammatory gene expression evoked by oxLDL.
出处 《河南医学研究》 CAS 2012年第1期4-7,共4页 Henan Medical Research
关键词 脂蛋白相关磷脂酶A2 单核细胞趋化蛋白-1 动脉粥样硬化 基因沉默 lipoprotein associated phospholipase A2 monocyte chemoattractant protein-1 atheroslerosis gene silencing
  • 相关文献

参考文献1

二级参考文献36

  • 1Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59.
  • 2Prescott SM, Zimmerman GA, Stafforini DM, Mclntyre TM. Platelet- activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-45.
  • 3Stafforini DM. Biology of platelet activating factor acetyhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009; 23: 73-83.
  • 4Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov 2008; 2: 72-6.
  • 5Miller RG, Costacou T, Orchard TJ. Lipoprotein-associated phos- pholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res 2010; 7: 47-55.
  • 6Wegner M, Araszkiewicz A, Piorunska-Mikolajczak A, Zozulinska- Ziolkiewicz D, Wierusz-Wysocka B, Piorunska-Stolzmann M. Theevaluation of 11_-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem 2009; 42: 1621-7.
  • 7Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Bio12005; 25: 923-31.
  • 8Wang WY, Li J, Yang D, Xu W, Zha RP, Wang YP. OxLDL stimulates lipo- protein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res 2010; 85: 845- 52.
  • 9MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife R J, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factoracetylhydrolase, generates two bioactive products during the oxidation of low-density Upoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-87,.
  • 10Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipido12003; 14: 421-30.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部